journal article·2025-12

Neonatal Liver‐Derived Extracellular Vesicle: Unlocking Mitochondrial Repair and Regenerative Mechanisms in Alcoholic Liver Disease

Xin Zeng, Wei Jiang, Shisheng Wang, Liqiang Hu, Yaojia Zhou, Qingmin Zeng, Xiong Pei, Jingping Liu, Qi Cao, Hong Tang, Dongbo Wu, Chengshi Wang

Small· Volume 21· Issue 49
Publisher page

Abstract

Abstract Alcoholic liver disease (ALD) represents a formidable global health challenge with limited effective therapeutic interventions. This study investigates the therapeutic potential and underlying mechanisms of xenogeneic neonatal liver‐derived extracellular vesicles in ALD. EV neo (neonatal rat liver‐derived extracellular vesicle) and EV adult (adult rat liver‐derived extracellular vesicle) are isolated via differential centrifugation and rigorously characterized. A preclinical ALD mouse model is established using the National Institute on Alcohol Abuse and Alcoholism model, with comparative therapeutic assessment of intravenously administered EV neo vs EV adult . Proteomic profiling of liver tissues and EVs (extracellular vesicles), integrated with immunohistochemical analyses, fluorescence imaging, mitochondrial functional assays, and quantification of inflammatory/regenerative markers, elucidated therapeutic mechanisms. Key findings demonstrate that EV neo ‐specific enrichment of mitochondrial biogenesis, anti‐inflammatory, and anti‐apoptotic pathways. EV neo administration significantly attenuates hepatic steatosis and inflammatory responses, restores mitochondrial homeostasis through redox balance modulation, induces macrophage polarization toward an M2 reparative phenotype, enhances hepatocyte proliferation, and suppresses apoptotic signaling. Comparative analysis revealed EV neo ’s superior therapeutic efficacy over EV adult , attributable to its developmentally programmed cargo that orchestrates mitochondrial resilience, immunometabolic reprogramming, and parenchymal regeneration. These findings establish developmental stage‐specific EV therapeutics as a paradigm for ALD treatment, emphasizing their multimodal mechanistic advantages in counteracting alcohol‐induced hepatopathology.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Alcohol Consumption and Health Effects · Liver Disease Diagnosis and Treatment · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center of Infectious Diseases Department of Liver Transplantation Center and National Health Commission (NHC) Key Laboratory of Transplant Engineering and Immunology West China Hospital Sichuan University Chengdu 610000 China

Center of Infectious Diseases West China Hospital of Sichuan University Chengdu Sichuan 610041 China

Laboratory of Infectious and Liver Diseases Institution of Infectious Diseases West China Hospital of Sichuan University Chengdu Sichuan 610041 China

Division of Infectious Diseases State Key Laboratory of Biotherapy Sichuan University Chengdu Sichuan 610041 China

West China Hospital Sichuan University Chengdu 610041 China

West China‐California Research Center for Predictive Intervention Medicine West China Hospital Sichuan University Chengdu 610041 China

Animal experimental center of West China hospital Sichuan University Chengdu 610041 China

Centre for Transplant and Renal Research Westmead Institute for Medical Research The University of Sydney 176 Hawkesbury Rd Westmead Sydney NSW 2145 Australia

Department of Endocrinology and Metabolism Laboratory of Diabetes and Metabolism Research West China Hospital Sichuan University Chengdu 610041 China

Funding

West China Hospital, Sichuan University

References (22)

Show source-provided references
1. 10.1016/j.jhep.2018.03.01810.1016/j.jhep.2018.03.018 ↗
2. 10.1002/hep.2325810.1002/hep.23258 ↗
3. 10.1111/liv.1570110.1111/liv.15701 ↗
4. 10.1111/j.1465-3362.2009.00153.x10.1111/j.1465-3362.2009.00153.x ↗
5. 10.1111/apt.1696910.1111/apt.16969 ↗
6. 10.1007/s10565-024-09954-610.1007/s10565-024-09954-6 ↗
7. 10.3390/ijms2512660410.3390/ijms25126604 ↗
8. 10.1002/adma.20230060210.1002/adma.202300602 ↗
9. 10.1016/j.phymed.2024.15618710.1016/j.phymed.2024.156187 ↗
10. 10.1002/jev2.7001110.1002/jev2.70011 ↗
11. 10.1007/s00109-024-02452-610.1007/s00109-024-02452-6 ↗
12. 10.1002/jev2.1213310.1002/jev2.12133 ↗
13. 10.1053/j.gastro.2015.06.00610.1053/j.gastro.2015.06.006 ↗
14. 10.1126/scitranslmed.aav852110.1126/scitranslmed.aav8521 ↗
15. 10.1016/j.actbio.2020.11.00110.1016/j.actbio.2020.11.001 ↗
16. 10.1016/j.biotechadv.2022.10798310.1016/j.biotechadv.2022.107983 ↗
17. 10.1126/science.120070810.1126/science.1200708 ↗
18. 10.1038/s41467-023-44057-610.1038/s41467-023-44057-6 ↗
19. 10.1038/s41575-018-0082-x10.1038/s41575-018-0082-x ↗
20. 10.1016/j.jhep.2017.02.02610.1016/j.jhep.2017.02.026 ↗
21. Fatty Liver and Alcoholic Liver Disease Study Group · Chin. J. Hepatol. · 2003 · 11 · 72
22. 10.1038/nprot.2013.03210.1038/nprot.2013.032 ↗